|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||0.0150 - 0.0165|
|52 Week Range||0.0045 - 0.0370|
|Beta (5Y Monthly)||0.30|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that it has successfully completed the twelve-months product stability testing required by the U.S. Food and Drug Administration (FDA) for its CypCaps™ final clinical trial product. This product will be used in the company’s planned clinical trial in locally advanced, inoperable pancreatic cancer upon the FDA lifting the clinical hold on PharmaCyte’s Investigational New Drug Application (IND).
PharmaCyte Biotech begins DNA sequence and stability studies in response to the FDA's requests for PharmaCyte's clinical trial product.
PharmaCyte Biotech begins testing of its clinical trial product in response to the FDA's recommendations to lift the clinical hold.